Found: 12
Select item for more details and to access through your institution.
A Novel Formulation of Tigecycline Has Enhanced Stability and Sustained Antibacterial and Antileukemic Activity.
- Published in:
- PLoS ONE, 2014, v. 9, n. 5, p. 1, doi. 10.1371/journal.pone.0095281
- By:
- Publication type:
- Article
A Porphodimethene Chemical Inhibitor of Uroporphyrinogen Decarboxylase.
- Published in:
- PLoS ONE, 2014, v. 9, n. 2, p. 1, doi. 10.1371/journal.pone.0089889
- By:
- Publication type:
- Article
Metabolic Adaptation to Chronic Inhibition of Mitochondrial Protein Synthesis in Acute Myeloid Leukemia Cells.
- Published in:
- PLoS ONE, 2013, v. 8, n. 3, p. 1, doi. 10.1371/journal.pone.0058367
- By:
- Publication type:
- Article
A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia.
- Published in:
- Cancer Medicine, 2016, v. 5, n. 11, p. 3031, doi. 10.1002/cam4.845
- By:
- Publication type:
- Article
A Phase I Study of the Metal Ionophore Clioquinol in Patients With Advanced Hematologic Malignancies.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2012, v. 12, n. 5, p. 330, doi. 10.1016/j.clml.2012.05.005
- By:
- Publication type:
- Article
The mitochondrial peptidase, neurolysin, regulates respiratory chain supercomplex formation and is necessary for AML viability.
- Published in:
- Science Translational Medicine, 2020, v. 12, n. 538, p. 1, doi. 10.1126/scitranslmed.aaz8264
- By:
- Publication type:
- Article
Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies.
- Published in:
- American Journal of Hematology, 2014, v. 89, n. 4, p. 363, doi. 10.1002/ajh.23640
- By:
- Publication type:
- Article
Carnitine transporter CT2 (SLC22A16) is over-expressed in acute myeloid leukemia (AML) and target knockdown reduces growth and viability of AML cells.
- Published in:
- Apoptosis, 2015, v. 20, n. 8, p. 1099, doi. 10.1007/s10495-015-1137-x
- By:
- Publication type:
- Article
Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.
- Published in:
- Signal Transduction & Targeted Therapy, 2022, v. 7, n. 1, p. 1, doi. 10.1038/s41392-021-00870-3
- By:
- Publication type:
- Article
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.
- Published in:
- Signal Transduction & Targeted Therapy, 2022, v. 7, n. 1, p. 1, doi. 10.1038/s41392-021-00870-3
- By:
- Publication type:
- Article
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.
- Published in:
- Signal Transduction & Targeted Therapy, 2022, v. 7, n. 1, p. 1, doi. 10.1038/s41392-021-00870-3
- By:
- Publication type:
- Article